Navigation Links
Sanofi-aventis Announces Good First-quarter 2009 Performance
Date:4/29/2009

duct candidate claiming to be biologically similar to Lovenox(R) must show therapeutic equivalence in terms of efficacy and safety in at least one adequately powered, randomized, double-blind, parallel group clinical trial. In the United States, no biosimilar of Lovenox(R) is approved at this point in time.

Lantus(R), the world's leading insulin brand, again reported strong growth (27.1%), driven by the Lantus(R) SoloSTAR(R) injection pen. Lantus(R) achieved significant growth in all three regions: 30.3% in the United States, 14.9% in Europe, and 43.5% in Other Countries. This performance keeps sanofi-aventis on track for achieving its goal of doubling net sales of Lantus(R) by 2012 (relative to the 2008 figure). On April 21, 2009, sanofi-aventis announced that it was making a new investment in China to produce Lantus(R) SoloSTAR(R) locally, in order to meet growing demand in the Chinese market and improve the treatment of diabetes in China.

Net sales of the rapid-acting insulin analog Apidra(R) rose by 42.9% to euro 31 million. In February, the FDA approved Apidra(R) SoloSTAR(R). This means that patients in the United States who use both Lantus(R) and Apidra(R) to help manage their blood sugar (basal-prandial insulin regimens) can now use one pen delivery device for each product, making administration of their insulins more convenient. Apidra(R) and Apidra(R) SoloSTAR(R) were approved in Japan on April 22, 2009.

Boosted by its use in adjuvant breast cancer treatment and in prostate cancer, Taxotere(R) performed well, especially in Europe and Other Countries, where sales rose by 8.1% (to euro 231 million) and by 18.9% (to euro 106 million) respectively. In Japan, net sales of the product were up 15.2% at euro 30 million, notably due to the prostate cancer indication approved in the sec
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
2. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
3. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
4. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
5. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
7. Sanofi-aventis Delivers 2008 Results Above Guidance
8. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
10. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... ... therapy for knee osteoarthritis is an important part of knee pain treatment. ... doing what they want or need to do. The patient may have trouble getting in ... exercise regime may be limited by the pain in their knee. When a patient sees ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... can be a very messy experience, especially when cracking eggs. Cracking an egg is ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2
... 26 Daniel S. Dueber, CEO of Coast Independent Review ... Investigations of the House Energy and Commerce Committee in the ... the Government Accountability Office (GAO) in a clandestine sting operation ... out despite the absence of proof that Coast had committed ...
... free radicals, researchers say , , THURSDAY, March 26 ... influence children,s lung growth and function, as well ... say University of Southern California researchers. , "Many ... genetic variation and environmental exposures such as tobacco ...
... Boston Scientific Corporation (NYSE: BSX ) today ... news announcements at the 58th Annual Scientific Session of ... runs from March 28-31 in Orlando, Florida. "We are ... from the landmark SYNTAX study, the only randomized trial ...
... Group, Inc. (NYSE Amex: QGP ) ( ... RedChip Companies Inc. to enhance its investor relations outreach ... in broadening visibility for emerging growth companies as well ... comprehensive platform of media services," said Noel J. Guillama, ...
... GUANGZHOU, China, March 26 /PRNewswire-Asia / -- ... Medicine" or "the Company"), a,developer and a ... Chinese medicines ("TCM"),nutritional and dietary-supplements, medical devices, ... China ("PRC"), today reported outstanding,financial results for ...
... is Alcohol Awareness MonthSEYMOUR, Tenn., March 26 Six ... on alcohol, according to the National Center on Addiction ... binge drinking in women,s colleges increased by 124 percent ... in need of but have not received treatment for ...
Cached Medicine News:Health News:Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful 2Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Boston Scientific Announces Schedule For ACC 2009 2Health News:Boston Scientific Announces Schedule For ACC 2009 3Health News:Boston Scientific Announces Schedule For ACC 2009 4Health News:Boston Scientific Announces Schedule For ACC 2009 5Health News:Boston Scientific Announces Schedule For ACC 2009 6Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 2Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 2Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 4Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 5Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 6Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 7Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 8Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 9Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 10Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 11Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 2Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 3
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Cloud-based Veeva CRM Now Deployed in Over 20 European ... Customer Summit kicking off this morning in Philadelphia, Veeva Systems ... Since Veeva,s official expansion into Europe in April 2010, the ... than 35 life sciences companies across 20+ different European markets. ...
... AB (OMX: MVIR), a research-based specialty pharmaceutical company focused ... Henric Juserius to be the new head of the ... for Medivir,s pharmaceutical marketing and sales, will join the ... the management team. Henric Juserius has a ...
Cached Medicine Technology:Veeva Systems Announces Dramatic Growth in Europe 2Veeva Systems Announces Dramatic Growth in Europe 3Veeva Systems Announces Dramatic Growth in Europe 4New Executive Vice President Commercial Appointed 2
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 3.5V halogen source....
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: